Clindamycin vs penicillin for anaerobic lung infections. High rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus. 1990

F Gudiol, and F Manresa, and R Pallares, and J Dorca, and G Rufi, and J Boada, and X Ariza, and A Casanova, and P F Viladrich
Infectious Disease Unit, Hospital of Bellvitge, Barcelona, Spain.

Thirty-seven adult patients with anaerobic lung infections (27 lung abscesses and 10 necrotizing pneumonias) were submitted to transthoracic needle-aspiration and/or bronchoscopic specimen brush cultures before therapy and thereafter in all cases considered to be failures. Patients were randomly assigned to receive either clindamycin, 600 mg intravenously every 6 hours, or penicillin G, 2 million U every 4 hours for no less than 8 days, until clinical and radiological improvement became apparent. Treatment was continued orally with clindamycin, 300 mg every 6 hours, or penicillin V, 750 mg every 6 hours, until completing a minimum of 4 weeks. Ten of the 47 anaerobes initially isolated from the lung (nine Bacteroides melaninogenicus and one Bacteroides capillosus) were resistant to penicillin, but none were resistant to clindamycin. Five of the nine patients harboring these penicillin-resistant Bacteroides received penicillin, and all failed to respond to therapy. Overall, eight of the 18 patients in the penicillin group and one of 19 in the clindamycin group failed to respond to therapy. These drugs were equally well tolerated in both groups. The presence of penicillin-resistant Bacteroides is a frequent cause of penicillin failure in patients with anaerobic lung infections. In this setting, clindamycin appears to be the current therapy of choice for initial treatment.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010403 Penicillin Resistance Nonsusceptibility of an organism to the action of penicillins. Penicillin Resistances,Resistance, Penicillin,Resistances, Penicillin
D010406 Penicillins A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D012141 Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. Respiratory System Infections,Upper Respiratory Tract Infection,Upper Respiratory Tract Infections,Infections, Respiratory,Infections, Respiratory Tract,Infections, Upper Respiratory,Infections, Upper Respiratory Tract,Respiratory Infections,Upper Respiratory Infections,Infection, Respiratory System,Infection, Respiratory Tract,Respiratory Infection, Upper,Respiratory System Infection,Respiratory Tract Infection
D002981 Clindamycin An antibacterial agent that is a semisynthetic analog of LINCOMYCIN. 7-Chloro-7-deoxylincomycin,Chlolincocin,Chlorlincocin,Cleocin,Clindamycin Hydrochloride,Clindamycin Monohydrochloride,Clindamycin Monohydrochloride, Monohydrate,Dalacin C,7 Chloro 7 deoxylincomycin,Hydrochloride, Clindamycin,Monohydrate Clindamycin Monohydrochloride,Monohydrochloride, Clindamycin,Monohydrochloride, Monohydrate Clindamycin
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

F Gudiol, and F Manresa, and R Pallares, and J Dorca, and G Rufi, and J Boada, and X Ariza, and A Casanova, and P F Viladrich
December 1983, Surgical neurology,
F Gudiol, and F Manresa, and R Pallares, and J Dorca, and G Rufi, and J Boada, and X Ariza, and A Casanova, and P F Viladrich
August 1982, JAMA,
F Gudiol, and F Manresa, and R Pallares, and J Dorca, and G Rufi, and J Boada, and X Ariza, and A Casanova, and P F Viladrich
August 1982, Journal - Connecticut State Dental Association,
F Gudiol, and F Manresa, and R Pallares, and J Dorca, and G Rufi, and J Boada, and X Ariza, and A Casanova, and P F Viladrich
March 1981, Journal of oral surgery (American Dental Association : 1965),
F Gudiol, and F Manresa, and R Pallares, and J Dorca, and G Rufi, and J Boada, and X Ariza, and A Casanova, and P F Viladrich
June 1965, The Journal of infectious diseases,
F Gudiol, and F Manresa, and R Pallares, and J Dorca, and G Rufi, and J Boada, and X Ariza, and A Casanova, and P F Viladrich
September 1983, Annals of internal medicine,
F Gudiol, and F Manresa, and R Pallares, and J Dorca, and G Rufi, and J Boada, and X Ariza, and A Casanova, and P F Viladrich
January 1984, Antimicrobial agents and chemotherapy,
F Gudiol, and F Manresa, and R Pallares, and J Dorca, and G Rufi, and J Boada, and X Ariza, and A Casanova, and P F Viladrich
April 1971, The American journal of the medical sciences,
F Gudiol, and F Manresa, and R Pallares, and J Dorca, and G Rufi, and J Boada, and X Ariza, and A Casanova, and P F Viladrich
April 1983, Annals of internal medicine,
F Gudiol, and F Manresa, and R Pallares, and J Dorca, and G Rufi, and J Boada, and X Ariza, and A Casanova, and P F Viladrich
January 1992, Terapevticheskii arkhiv,
Copied contents to your clipboard!